Answers are grounded in this paper and cite their sources.
Tumor necrosis factor (TNF)-α antagonists are promising therapeutic agents for patients with severe autoimmune and rheumatologic conditions. Unfortunately, their use has been associated with an increased rate of tuberculosis, endemic mycoses, and intracellular bacterial infections. Infliximab, 1 of 3 available drugs in this novel class, appears to be associated with the greatest risk of infection, likely because of its long half-life and induction of monocyte apoptosis. Prospective trials are necessary to determine the exact risk associated with these agents, particularly the newer TNF-α antagonists. More specific TNF-α blockers, which reduce inflammation while maintaining adequate immunity, are needed. In the meantime, a thorough work-up is mandatory for all febrile illness occurring in TNF-α blocker recipients. We present 4 patients who developed severe infections during TNF-α antagonist therapy, review the literature, and discuss current guidelines for surveillance and prophylaxis. Abbreviations: AIDS = acquired immunodeficiency syndrome, FDA = United States Food and Drug Administration, HIV = human immunodeficiency virus, PPD = purified protein derivative, RA = rheumatoid arthritis, TB = tuberculosis, TH1 = T-helper type 1, TNF = tumor necrosis factor, WBC = white blood cell count.
No takes yet. Share an insight, caveat, or question.
Crum et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: